W518107

スクロース アセタート イソブチラート

• 別名: SAIB
• 実験式（ヒル表記法）: C₄₀H₆₂O₁₉
• 分子量: 846.91
• MDL番号: MFCD00041859
• UNSPSCコード: 12164502
• PubChem Substance ID: 24902076
• NACRES: NA.21

特性

• 由来生物: synthetic
• 品質水準: 400
• グレード: Kosher
• bp: 288 °C
• 密度: 1.146 g/mL at 25 °C
• アプリケーション: flavors and fragrances
• 文書: see Safety & Documentation for available documents
• 食物アレルゲン: no known allergens
• 官能: odorless
• SMILES記法: CC(C)C(=O)OC[C@]1(O[C@H](COC(C)=O)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@H]2OC(=O)C(C)C
• InChI: 1S/C40H62O19/c1-18(2)33(43)51-17-40(32(57-38(48)23(11)12)29(54-35(45)20(5)6)27(58-40)16-50-25(14)42)59-39-31(56-37(47)22(9)10)30(55-36(46)21(7)8)28(53-34(44)19(3)4)26(52-39)15-49-24(13)41/h18-23,26-32,39H,15-17H2,1-14H3/t26-,27-,28-,29-,30+,31-,32+,39-,40+/m1/s1
• InChI Key: ZNEBZIJCDDCNRC-SWTLDUCYSA-N

詳細

アプリケーション

• An ultrasound-triggered injectable sodium alginate scaffold loaded with electrospun microspheres for on-demand drug delivery to accelerate bone defect regeneration.: This study highlights the use of Sucrose Acetate Isobutyrate (SAIB) in developing advanced drug delivery systems. SAIB is utilized to enhance the stability and controlled release properties of drug-loaded microspheres integrated into sodium alginate scaffolds, offering precise therapeutic management in bone regeneration applications (Yi Y et al., 2024).


• Sustained Release of Dexamethasone from 3D-Printed Scaffolds Modulates Macrophage Activation and Enhances Osteogenic Differentiation.: Incorporating SAIB into 3D-printed scaffolds has shown to effectively control the release rates of dexamethasone, a therapeutic agent, facilitating improved osteogenic differentiation and reduced inflammatory responses, crucial for bone healing and regeneration (Majrashi M et al., 2023).


• Application of Sucrose Acetate Isobutyrate in Development of Co-Amorphous Formulations of Tacrolimus for Bioavailability Enhancement.: Research demonstrates how SAIB can be used to develop co-amorphous drug formulations, specifically for tacrolimus, to enhance its bioavailability. This approach addresses significant challenges in drug solubility and stability, marking a significant advance in the formulation of poorly water-soluble drugs (Mohamed EM et al., 2023).

免責事項

For R&D or non-EU Food use. Not for retail sale.

安全性情報

• 保管分類コード: 10 - Combustible liquids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable
• 個人用保護具 (PPE): Eyeshields, Gloves